RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
27.88
+0.14 (+0.52%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close27.74
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,273,596
Market Cap191.167B
Beta0.53
PE Ratio (TTM)21.30
EPS (TTM)1.31
Earnings DateN/A
Forward Dividend & Yield1.11 (3.95%)
Ex-Dividend Date2018-03-15
1y Target Est35.67
Trade prices are not sourced from all markets
  • Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
    Zacks19 hours ago

    Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

    Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

  • Reuters21 hours ago

    FDA declines to approve Pfizer biosimilar of Roche's cancer drug

    Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.

  • MarketWatch22 hours ago

    Pfizer says FDA failed to approve Herceptin biosimilar

    Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...

  • Business Wireyesterday

    New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis

    OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration. New safety data remain consistent with OCREVUS’ favorable benefit-risk profile in both relapsing and primary progressive multiple sclerosis (PPMS).

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks4 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • Moody's5 days ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • PR Newswire5 days ago

    Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®

    - New indication as a companion diagnostic with AstraZeneca's TAGRISSO® (osimertinib) in first line treatment of patients with non-small cell lung cancer (NSCLC) - Results for EGFR mutations can be available ...

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks5 days ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
    Market Realist6 days ago

    How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017

    In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters6 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters6 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters6 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist7 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • Reuters7 days ago

    Roche's Hemlibra gets speedy FDA review for wider use

    Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.

  • Business Wire7 days ago

    FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia a Without Inhibitors

    Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to HEMLIBRA® for people with hemophilia A without factor VIII inhibitors.

  • How AbbVie’s Humira Performed in 4Q17 and 2017
    Market Realist8 days ago

    How AbbVie’s Humira Performed in 4Q17 and 2017

    AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist8 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • PR Newswire8 days ago

    Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems

    OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for cobas® CT/NG for use on the cobas® 6800/8800 Systems for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in both symptomatic and asymptomatic individuals. "cobas CT/NG on the cobas 6800/8800 Systems provides clinicians with results in which they can have high confidence given the excellent sensitivity and specificity of the assay for all relevant sample types," said Barbara Van der Pol, international expert on STIs and Associate Professor of Medicine, School of Medicine, University of Alabama at Birmingham.

  • Business Wire8 days ago

    Genentech to Present New Data at AAN Highlighting Extensive Research for OCREVUS and Expanding Neuroscience Pipeline

    Genentech, a member of the Roche Group , announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology Annual Meeting from April 21-27 in Los Angeles, California.

  • Roche on Damage Control after Hemlibra Patient Deaths
    Market Realist11 days ago

    Roche on Damage Control after Hemlibra Patient Deaths

    The news that five patients on Roche’s (RHHBY) hemophilia drug Hemlibra died triggered the company’s stock to decline ~2% on March 28, 2018. It also announced that it has received a favorable ruling in a Japanese court in a patent-infringement litigation with Shire (SHPG).

  • Roche’s Ocrevus Is a Highly Effective Option for MS Treatment
    Market Realist12 days ago

    Roche’s Ocrevus Is a Highly Effective Option for MS Treatment

    Roche’s (RHHBY) Ocrevus, approved by the FDA in March 2017, is targeted at the treatment of relapsing and primary progressive forms of multiple sclerosis (or MS). Ocrevus was also approved in the European Union (or EU) for these two forms of MS in January 2018. With its rising market share, Ocrevus is a highly effective treatment option for MS, offering a highly favorable risk-benefit profile as demonstrated in three Phase 3 studies of the drug.

  • Roche Gets Lung Cancer Drug Alecensa Approval in Swiss Market
    Market Realist12 days ago

    Roche Gets Lung Cancer Drug Alecensa Approval in Swiss Market

    On April 3, 2018, Roche Holding (RHHBY) announced that its drug Alecensa has been approved in Switzerland as a first-line treatment for advanced or metastatic ALK (anaplastic lymphoma kinase)-positive NSCLC (non-small cell lung cancer). The drug was previously approved in Switzerland for treating patients with advanced or metastatic ALK-positive NSCLC that worsened after treatment with Pfizer’s (PFE) anti-cancer drug crizotinib and who could not tolerate crizotinib treatment.

  • Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis
    Market Realist12 days ago

    Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis

    On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE (National Institute for Health and Care Excellence) in England for the treatment of relapsing forms of MS in adults. Ocrevus was approved by the FDA for the treatment of adult patients suffering from relapsing-remitting MS or a primary progressive form of MS, which is more difficult to treat. The drug is the only approved therapy for the primary progressive form of MS and has given stiff competition to Merck’s (MRK) market-leading MS drug Rebif. Roche offered the drug at a 25% discount to Rebif.

  • Recent Developments with Roche’s Lung Cancer Drug Tecentriq
    Market Realist12 days ago

    Recent Developments with Roche’s Lung Cancer Drug Tecentriq

    On April 9, 2018, Roche (RHHBY) announced that it has received approval for Tecentriq from NICE (National Institute for Health and Care Excellence) in England for the treatment of the most common form of lung cancer. Patients with advanced NSCLC (non-small cell lung cancer) who have undergone chemotherapy for the disease but still registered disease progression can now get immunotherapy through the NHS (National Health Service), which will provide coverage for Tecentriq treatment.

  • What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength
    Simply Wall St.12 days ago

    What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Roche Holding AG (SWX:ROG) a safer option. Doing business globally, large caps tend to haveRead More...